Overview

Efficacy, Safety and Tolerability of Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease Switched From Cholinesterase Inhibitors

Status:
Completed

Trial end date:
2013-12-01

Target enrollment:

Participant gender:

Summary

This is a multicenter study to evaluate the efficacy, safety and tolerability of Rivastigmine patch in patients with mild to moderate Alzheimer's disease switched from Cholinesterase Inhibitors.

Phase:

Phase 4

Details

Lead Sponsor:

Novartis Pharmaceuticals

Collaborator:

Ono Pharmaceutical Co. Ltd

Treatments:

Cholinesterase Inhibitors
Rivastigmine